CorMedix Inc. - 8-K Filing

CorMedix reports Q3 2026 consolidated revenue of $54.5 million and announces definitive agreement to acquire Heron Therapeutics assets. (Items: 2.02 Results of Operations and Financial ConditionOn November 12, 2026, CorMedix Inc, 9.01 Financial Statements and Exhibits(d) ExhibitsExhibit No)

SEC EDGAR · November 12, 2026, 13:00 UTC

Tickers: $CRMD

Read the full article at SEC EDGAR

Part of the story Altimmune, Inc. - 8-K Filing (3 articles)

More Regulatory news

FILANA THERAPEUTICS, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 13:18 UTC
RUM Group Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:17 UTC
Theriva Biologics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SeaStar Medical Holding Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
Avalyn Pharma Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SES AI Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
Data443 Risk Mitigation, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
TRUSTMARK CORP - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SUBURBAN PROPANE PARTNERS LP - 8-K Filing SEC EDGAR · November 12, 2026, 13:14 UTC
MeiraGTx Holdings plc - 10-Q Filing SEC EDGAR · November 12, 2026, 13:13 UTC